New Zealand reduces fees, changes abbreviated review rules
This article was originally published in SRA
New Zealand’s regulatory agency Medsafe has reduced the fees payable for applications for approval of innovative new medicines and for clinical trial approvals1. While the new fees applied from 8 April, the regulatory authority is holding a consultation, and any feedback received by a 22 May deadline will be considered and may result in adjustments.
You may also be interested in...
New Zealand's medicines regulator plans to increase the fees it charges for various regulatory activities as of June this year. In 2009, the agency had reduced its fees by approximately 12% as its coffers were full and the industry was then told that there would be no changes until the surplus was cleared.
A lack of regulatory harmonization for dietary supplements in Asia is a big challenge facing companies operating in the region, according to experts from the Asia Regulatory Professionals Association. The ARPA is looking to start a conversation on the issue which the association hopes will lead to regulatory change.
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.